Asset Details
Do you wish to reserve the book?
Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury
Do you wish to request the book?
Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury
2025
Overview
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, significantly improving patient survival. However, their use is frequently associated with immune-related adverse events, including immune checkpoint inhibitor-induced liver injury (ICI-DILI), which poses substantial clinical challenges. While corticosteroid therapy remains the primary treatment for ICI-DILI, many patients with steroid-refractory cases, especially those involving non-hepatocellular injury, exhibit resistance to standard therapies. Emerging evidence suggests that factors such as MDR1 expression, PD-L1 (Programmed cell death ligand (1)) and PD-L2 (Programmed cell death ligand (2)) expression levels, and liver injury patterns contribute to steroid resistance, highlighting the need for alternative treatment strategies. Recent advancements in therapeutic research have identified promising second-line treatments, including immunosuppressants (tacrolimus, cyclosporine A, mycophenolate mofetil, and azathioprine), monoclonal antibodies (infliximab and tocilizumab), anti-thymocyte globulin, intravenous immunoglobulin, ursodeoxycholic acid for cholestatic cases, and blood purification techniques. These innovations offer new possibilities for managing steroid-refractory ICI-DILI. This review also explores critical gaps in the field, including the lack of reliable diagnostic criteria and biomarkers for hormone-refractory ICI-DILI. Furthermore, we discuss the development of novel therapies informed by evolving insights into the condition’s pathogenesis and the feasibility of reintroducing ICIs after ICI-DILI resolution. These advancements mark significant progress in optimizing patient outcomes and advancing the mechanistic understanding of ICI-DILI.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Chemical and Drug Induced Liver Injury - diagnosis
/ Chemical and Drug Induced Liver Injury - drug therapy
/ Chemical and Drug Induced Liver Injury - etiology
/ Chemical and Drug Induced Liver Injury - therapy
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - adverse effects
/ Immunosuppressive Agents - therapeutic use
/ Liver
/ Medicine
/ Melanoma
/ Oncology
/ Patients
/ Proteins
/ Review
/ Steroids
/ Toxicity
We currently cannot retrieve any items related to this title. Kindly check back at a later time.